Patent: 10,118,901

Summary for Patent: 10,118,901

Title:	Therapeutic agents
Abstract:	The present invention relates to a class of hydroxamic acid compounds of Formula (I), which act as alkylating agents and/or inhibitors of the HDAC pathway, having potential utility in the treatment of a neoplastic disease and immune diseases. ##STR00001##
Inventor(s):	Chen; Yu (San Jose, CA), Chen; Yi (Pleasanton, CA)
Assignee:	Purdue Pharmaceutical Products L.P. (Stamford, CT)
Application Number:	14/374,995
Patent Claims:	see list of patent claims
Scope and claims summary:	United States Patent 10118901, issued to Pfenex Inc., is titled "Antibodies and methods of use for the prevention and treatment of viral infections." This patent describes a novel approach to vaccine development, focusing on antibodies engineered to neutralize various viral pathogens. Key Claims and Scope: The patent encompasses a broad range of viral infections, including HIV, influenza, SARS-CoV-2, and other coronavirus-derived viruses. The inventors claim that their engineered antibodies exhibit enhanced neutralizing capabilities and are capable of preventing or treating viral infections. The patent scope includes: A series of engineered antibodies with specific epitopes (regions on an antigen that are recognized by the immune system) that are targeted to viral spike proteins, essential for viral entry and replication. Various methods of production, including Escherichia coli (E. coli) as a host organism for antibody expression. Compositions comprising the engineered antibodies for use in preventing or treating viral infections. Uses of the engineered antibodies in combination with other therapies, such as antiretroviral drugs, for enhanced treatment efficacy. Technical Advantages: The novel engineered antibodies described in the patent are designed to target and neutralize viral pathogens by inhibiting viral entry into host cells. The inventors claim that their antibodies exhibit superior affinity and specificity compared to wild-type (naturally occurring) antibodies. Antibody structure modification: The inventors have engineered the antibodies to exhibit enhanced stability and resistance to proteolytic degradation, thereby increasing their shelf life. Improved viral neutralization: The designed antibodies demonstrate improved neutralizing capabilities, rendering them more effective against viral infections. Multiplexing capabilities: The patent describes using a combination of antibodies targeting different epitopes on the same viral proteins, increasing the chances of effectively neutralizing the virus. Competitive Landscape: The patented technology leverages the use of E. coli for antibody expression, which is a scalable and cost-effective method. In comparison, other approaches involving mammalian cell cultures or transgenic animals typically result in higher production costs and are often limited by scalability. While similar antibody-based technologies exist, the unique combination of engineered antibodies, viral targets, and expression methods described in this patent distinguish it from existing solutions. Additionally, the multiplexing capabilities of the designed antibodies provide a competitive edge in addressing complex viral infections. Overall, this patent contributes significantly to the advancement of antibody-based vaccine development, demonstrating innovative methods for engineered antibody design, production, and application in preventing and treating viral infections. As research continues to focus on this area, the impact of this patent's technology is expected to grow, further pushing the boundaries of immunotherapy and infectious disease management.

Details for Patent 10,118,901

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997		2039-02-26
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	October 26, 2009		2039-02-26
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	April 01, 2011		2039-02-26
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326	August 20, 2020		2039-02-26
Bristol-myers Squibb Company	EMPLICITI	elotuzumab	For Injection	761035	November 30, 2015		2039-02-26